Craig Hallum restated their buy rating on shares of Encompass Health (AMEX:EHC) in a report issued on Monday, The Fly reports. They currently have a $76.00 price target on the stock, down from their prior price target of $81.00.
A number of other research firms have also recently commented on EHC. Barclays raised Encompass Health from an equal weight rating to an overweight rating and boosted their price target for the stock from $68.00 to $70.00 in a report on Thursday, May 30th. BMO Capital Markets began coverage on Encompass Health in a report on Thursday, June 27th. They set an outperform rating and a $72.00 price objective on the stock. Piper Jaffray Companies set a $77.00 price objective on Encompass Health and gave the stock a buy rating in a report on Wednesday, July 31st. Zacks Investment Research cut Encompass Health from a hold rating to a sell rating in a report on Tuesday, July 30th. Finally, Raymond James decreased their price objective on Encompass Health from $80.00 to $75.00 and set an outperform rating on the stock in a report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $75.14.
Encompass Health has a twelve month low of $40.86 and a twelve month high of $59.29.
Encompass Health Company Profile
Encompass Health Corporation, formerly HealthSouth Corporation, is a provider of post-acute healthcare services, offering both facility-based and home-based post-acute services in 35 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies.
Further Reading: What is insider trading?
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.